CN111770753A - 增强和/或稳定患有法布里病患者的心脏功能的方法 - Google Patents

增强和/或稳定患有法布里病患者的心脏功能的方法 Download PDF

Info

Publication number
CN111770753A
CN111770753A CN201880056413.8A CN201880056413A CN111770753A CN 111770753 A CN111770753 A CN 111770753A CN 201880056413 A CN201880056413 A CN 201880056413A CN 111770753 A CN111770753 A CN 111770753A
Authority
CN
China
Prior art keywords
migalastat
patient
salt
mwfs
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880056413.8A
Other languages
English (en)
Chinese (zh)
Inventor
杰夫·卡斯特利
杰伊·巴斯
尼娜·斯库班
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicus Therapeutics Inc
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63528948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111770753(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of CN111770753A publication Critical patent/CN111770753A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880056413.8A 2017-08-28 2018-08-28 增强和/或稳定患有法布里病患者的心脏功能的方法 Pending CN111770753A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762550984P 2017-08-28 2017-08-28
US62/550,984 2017-08-28
PCT/US2018/048257 WO2019046244A1 (en) 2017-08-28 2018-08-28 METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE

Publications (1)

Publication Number Publication Date
CN111770753A true CN111770753A (zh) 2020-10-13

Family

ID=63528948

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880056413.8A Pending CN111770753A (zh) 2017-08-28 2018-08-28 增强和/或稳定患有法布里病患者的心脏功能的方法

Country Status (26)

Country Link
US (1) US20200222377A1 (https=)
EP (3) EP3675853B1 (https=)
JP (3) JP7755929B2 (https=)
KR (2) KR20250049561A (https=)
CN (1) CN111770753A (https=)
AR (1) AR112482A1 (https=)
AU (2) AU2018326364B2 (https=)
CA (1) CA3074450C (https=)
CL (1) CL2020000491A1 (https=)
DK (2) DK3675853T3 (https=)
EA (1) EA202090564A1 (https=)
ES (2) ES2931054T3 (https=)
FI (1) FI4176877T3 (https=)
HR (2) HRP20250064T1 (https=)
HU (2) HUE060287T2 (https=)
IL (3) IL272893B2 (https=)
LT (2) LT3675853T (https=)
MX (2) MX2020002229A (https=)
PL (2) PL4176877T3 (https=)
PT (2) PT3675853T (https=)
RS (2) RS66515B1 (https=)
SG (1) SG11202001707PA (https=)
SI (1) SI4176877T1 (https=)
SM (2) SMT202500073T1 (https=)
TW (1) TWI845479B (https=)
WO (1) WO2019046244A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114423428A (zh) * 2019-08-07 2022-04-29 阿米库斯治疗学公司 治疗在gla基因中具有突变的患者的法布里病的方法
CN119120696A (zh) * 2024-11-12 2024-12-13 北京贝瑞和康生物技术有限公司 检测法布雷病gla基因突变的引物组、试剂盒及其应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2533050T6 (pl) 2006-05-16 2016-05-31 Amicus Therapeutics Inc Możliwości leczenia choroby Fabry'ego
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
CA3224546C (en) 2017-05-30 2026-02-24 Amicus Therapeutics, Inc. Use of migalastat in the treatment of fabry patients
US20200222377A1 (en) 2017-08-28 2020-07-16 Amicus Therapeutics, Inc. Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease
KR20200128676A (ko) 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
US12594268B2 (en) 2018-08-20 2026-04-07 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
TR2024011149A1 (tr) 2024-08-23 2026-03-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Mi̇galastat i̇çeren kapsül formülasyonlari

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160324839A1 (en) * 2007-04-26 2016-11-10 Amicus Therapeutics, Inc. Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
US20200222377A1 (en) 2017-08-28 2020-07-16 Amicus Therapeutics, Inc. Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease
EP3676914B1 (en) 2017-08-28 2023-08-16 John Mezzalingua Associates LLC Weather protecting (wp) housing for coaxial cable connectors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160324839A1 (en) * 2007-04-26 2016-11-10 Amicus Therapeutics, Inc. Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A MEHTA 等，: "Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data", 《LANCET》 *
D.P. GERMAIN 等，: "Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat", 《N. ENGL. J. MED.》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114423428A (zh) * 2019-08-07 2022-04-29 阿米库斯治疗学公司 治疗在gla基因中具有突变的患者的法布里病的方法
CN119120696A (zh) * 2024-11-12 2024-12-13 北京贝瑞和康生物技术有限公司 检测法布雷病gla基因突变的引物组、试剂盒及其应用

Also Published As

Publication number Publication date
US20200222377A1 (en) 2020-07-16
MX2023005628A (es) 2023-05-24
SMT202500073T1 (it) 2025-03-12
CA3074450C (en) 2024-10-01
JP2020531550A (ja) 2020-11-05
AR112482A1 (es) 2019-10-30
SG11202001707PA (en) 2020-03-30
RS63742B1 (sr) 2022-12-30
ES3013820T3 (en) 2025-04-15
AU2018326364B2 (en) 2024-08-29
IL272893A (en) 2020-04-30
EP4176877A1 (en) 2023-05-10
AU2018326364A1 (en) 2020-04-09
IL272893B2 (en) 2024-07-01
DK3675853T3 (da) 2022-11-28
FI4176877T3 (fi) 2025-03-06
LT4176877T (lt) 2025-02-10
HUE070433T2 (hu) 2025-06-28
EP4176877B1 (en) 2024-12-04
MX2020002229A (es) 2020-07-20
IL310648A (en) 2024-04-01
LT3675853T (lt) 2022-12-12
KR20200044908A (ko) 2020-04-29
TWI845479B (zh) 2024-06-21
BR112020003974A2 (pt) 2020-09-01
CL2020000491A1 (es) 2020-09-11
KR102790184B1 (ko) 2025-04-01
CA3074450A1 (en) 2019-03-07
PT3675853T (pt) 2022-11-28
WO2019046244A1 (en) 2019-03-07
HUE060287T2 (hu) 2023-02-28
AU2024266945A1 (en) 2024-12-19
JP2025138638A (ja) 2025-09-25
HRP20221366T1 (hr) 2023-01-06
IL272893B1 (en) 2024-03-01
JP2023051998A (ja) 2023-04-11
EP3675853A1 (en) 2020-07-08
HRP20250064T1 (hr) 2025-03-14
SI4176877T1 (sl) 2025-03-31
EA202090564A1 (ru) 2020-06-15
KR20250049561A (ko) 2025-04-11
RS66515B1 (sr) 2025-03-31
PL3675853T3 (pl) 2022-12-27
EP4588476A1 (en) 2025-07-23
PT4176877T (pt) 2025-02-24
IL324182A (en) 2025-12-01
JP7755929B2 (ja) 2025-10-17
EP3675853B1 (en) 2022-09-07
SMT202200459T1 (it) 2023-01-13
TW201919619A (zh) 2019-06-01
PL4176877T3 (pl) 2025-04-07
DK4176877T3 (da) 2025-02-24
ES2931054T3 (es) 2022-12-23

Similar Documents

Publication Publication Date Title
JP7784398B2 (ja) Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
KR102631805B1 (ko) 신장 손상을 갖는 파브리 환자를 치료하는 방법
KR102790184B1 (ko) 파브리병을 앓는 환자에서 심장 기능을 강화 및/또는 안정화시키는 방법
AU2025217396A1 (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
JP2024122992A (ja) Ｇｌａ遺伝子にｇ９３３１ａ変異を有する患者においてファブリー病を処置する方法
AU2025200074A1 (en) Treatment of patients with classic fabry disease
JP2025131572A (ja) 腎機能障害を有する患者のファブリー病を治療する方法
AU2024278298A1 (en) Use of migalastat for treating fabry disease in pregnant patients
JP2025128105A (ja) ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用
JP2026016375A (ja) Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
CN111278438A (zh) 治疗具有肾损害的法布里患者的方法
HK40039916A (en) Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
HK40085360A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40044440A (en) Treatment of patients with classic fabry disease
HK40031708A (en) Methods of treating fabry patients having renal impairment
HK40044013A (en) Use of migalastat for treating fabry disease in pregnant patients
HK40001720A (en) Methods of treating fabry disease in patients having the g9331a mutation in the gla gene

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40039916

Country of ref document: HK